Prognostic factors in follicular lymphoma

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2902-2913

  Relander, Thomas ^a   Johnson, Nathalie A ^a   Farinha, Pedro ^a   Connors, Joseph M ^a   Sehn, Laurie H ^a   Gascoyne, Randy D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD103 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LACTATE DEHYDROGENASE; MESSENGER RNA; PREDNISONE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P53; RITUXIMAB; SERUM ALBUMIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CYTOGENETICS; DISEASE COURSE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; KARYOTYPING; LIFE EXPECTANCY; MACROPHAGE; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; PATHOLOGY;

HUMANS; LYMPHOMA, FOLLICULAR; PROGNOSIS;

EID: 77956114814     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.1693     Document Type: Review

References (188)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
2. Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations: Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9:717-720, 1998 (Pubitemid 28394156)
3. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes: Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998 (Pubitemid 28363044)
4. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986 (Pubitemid 17183570)
5. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984 (Pubitemid 15211022)
6. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
7. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003 (Pubitemid 36976715)
8. Al-Tourah AJ, Gill KK, Chhanabhai M, et al: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 26:5165-5169, 2008
9. Montoto S, Davies AJ, Matthews J, et al: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426-2433, 2007 (Pubitemid 47007616)
10. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996 (Pubitemid 26105537)
11. Wilder RB, Jones D, Tucker SL, et al: Longterm results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51:1219-1227, 2001 (Pubitemid 33116314)
12. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires: Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117, 1997 (Pubitemid 27106296)
13. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998 (Pubitemid 28363048)
14. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999 (Pubitemid 29022402)
15. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
16. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
17. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
18. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006 (Pubitemid 44794222)
19. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
20. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993 (Pubitemid 23307906)
21. McManus BM, Gascoyne RD: Pathology and laboratory medicine. JAMA 277:1887-1889, 1997
22. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
23. Martin AR, Weisenburger DD, Chan WC, et al: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85:3671-3678, 1995
24. Federico M, Vitolo U, Zinzani PL, et al: Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 95:783-789, 2000 (Pubitemid 30062696)
25. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
26. Buske C, Hoster E, Dreyling M, et al: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504-1508, 2006 (Pubitemid 44321768)
27. Montoto S, Lopez-Guillermo A, Altes A, et al: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 15: 1484-1489, 2004 (Pubitemid 39409738)
28. Gine E, Montoto S, Bosch F, et al: The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539-1545, 2006 (Pubitemid 44542041)
29. Perea G, Altes A, Montoto S, et al: Prognostic indexes in follicular lymphoma: A comparison of different prognostic systems. Ann Oncol 16:1508-1513, 2005 (Pubitemid 41222424)
30. Federico M, Bellei M, Marcheselli L, et al: Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555-4562, 2009
31. Reference deleted
32. Bastion Y, Berger F, Bryon PA, et al: Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2:123-129, 1991 (suppl 2)
33. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol 11:137-140, 2000 (suppl 1)
34. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993 (Pubitemid 23105672)
35. Canioni D, Brice P, Lepage E, et al: Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: A study from the Groupe d'Etude des Lymphomes Folliculaires. Br J Haematol 126:364-371, 2004 (Pubitemid 39005716)
36. Romaguera JE, McLaughlin P, North L, et al: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol 9:762-769, 1991
37. Lee MS, Chang KS, Cabanillas F, et al: Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237:175-178, 1987 (Pubitemid 17095920)
38. Berinstein NL, Reis MD, Ngan BY, et al: Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. J Clin Oncol 11:1344-1352, 1993 (Pubitemid 23199140)
39. Albinger-Hegyi A, Hochreutener B, Abdou MT, et al: High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: Improved polymerase chain reaction protocols for their detection. Am J Pathol 160:823-832, 2002 (Pubitemid 34224572)
40. Cleary ML, Galili N, Sklar J: Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 164:315-320, 1986 (Pubitemid 16069242)
41. Cleary ML, Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 82:7439-7443, 1985 (Pubitemid 16196835)
42. Gribben JG, Freedman A, Woo SD, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991
43. Hirt C, Dolken G: Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant 25:419-426, 2000 (Pubitemid 30114037)
44. Johnson PW, Price CG, Smith T, et al: Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 12:798-805, 1994
45. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: The clinical significance of molecular response in indolent follicular lymphomas. Blood 91: 2955-2960, 1998 (Pubitemid 28227546)
46. Rambaldi A, Carlotti E, Oldani E, et al: Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and longterm outcome in follicular non-Hodgkin lymphoma. Blood 105:3428-3433, 2005 (Pubitemid 40628182)
47. Gribben JG, Neuberg D, Freedman AS, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993 (Pubitemid 23172933)
48. Price CG, Meerabux J, Murtagh S, et al: The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 9:1527-1532, 1991
49. Finke J, Slanina J, Lange W, et al: Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol 11:1668-1673, 1993 (Pubitemid 23277317)
50. Liu Y, Hernandez AM, Shibata D, et al: BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 91:8910-8914, 1994
51. Summers KE, Goff LK, Wilson AG, et al: Frequency of the Bcl-2/IgH rearrangement in normal individuals: Implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 19:420-424, 2001 (Pubitemid 32112854)
52. Siddiqui M, Ristow K, Markovic SN, et al: Absolute lymphocyte count predicts overall survival in follicular lymphomas. Brit J Haematol 134:596-601, 2006 (Pubitemid 44253601)
53. Litam P, Swan F, Cabanillas F, et al: Prognostic value of serum beta-2 microglobulin in lowgrade lymphoma. Ann Intern Med 114:855-860, 1991
54. Seymour JF, Pro B, Fuller LM, et al: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003 (Pubitemid 46606360)
55. Ganti AK, Weisenburger DD, Smith LM, et al: Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience. Ann Oncol 17:920-927, 2006 (Pubitemid 43778981)
56. Wendum D, Sebban C, Gaulard P, et al: Follicular large-cell lymphoma treated with intensive chemotherapy: An analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma: Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1654-1663, 1997 (Pubitemid 27167406)
57. Montoto S, Lopez-Guillermo A, Ferrer A, et al: Survival after progression in patients with follicular lymphoma: Analysis of prognostic factors. Ann Oncol 13:523-530, 2002 (Pubitemid 34461134)
58. Pedersen LM, Sorensen PG: Urinary albumin excretion is a predictor of response to treatment and disease progression in low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 45:547-551, 2004 (Pubitemid 38196038)
59. Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94: 3334-3339, 1999 (Pubitemid 29536126)
60. Bono P, Teerenhovi L, Joensuu H: Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 97:2767-2775, 2003 (Pubitemid 36605144)
61. Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90:3167-3172, 1997 (Pubitemid 27444212)
62. Salles G, Bienvenu J, Bastion Y, et al: Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol 93:352-359, 1996 (Pubitemid 26148739)
63. Giles FJ, Vose JM, Do KA, et al: Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 28:595-604, 2004 (Pubitemid 38543196)
64. Warzocha K, Salles G, Bienvenu J, et al: Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia 11:441-443, 1997
65. Warzocha K, Ribeiro P, Bienvenu J, et al: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:3574-3581, 1998 (Pubitemid 28225722)
66. Zinzani PL, Baccini C, Zaccaria A, et al: Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur J Haematol 57:335-340, 1996 (Pubitemid 27008284)
67. Christiansen I, Gidlof C, Kalkner KM, et al: Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. Br J Haematol 92:639-646, 1996 (Pubitemid 26076765)
68. Salven P, Orpana A, Teerenhovi L, et al: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood 96:3712-3718, 2000
69. Swerdlow SH, Campo E, Lee Harris N, et al: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press 2008
70. Hans CP, Weisenburger DD, Vose JM, et al: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363-2367, 2003 (Pubitemid 36302082)
71. Ott G, Katzenberger T, Lohr A, et al: Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806-3812, 2002 (Pubitemid 34534555)
72. Warnke RA, Kim H, Fuks Z, et al: The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: Significance and clinicopathologic correlation. Cancer 40:1229-1233, 1977 (Pubitemid 8219479)
73. Chau I, Jones R, Cunningham D, et al: Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy? Br J Cancer 89:36-42, 2003
74. Bartlett NL, Rizeq M, Dorfman RF, et al: Follicular large-cell lymphoma: Intermediate or low grade? J Clin Oncol 12:1349-1357, 1994
75. Rodriguez J, McLaughlin P, Hagemeister FB, et al: Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features. Blood 93:2202-2207, 1999 (Pubitemid 29153621)
76. Miller TP, LeBlanc M, Grogan TM, et al: Follicular lymphomas: Do histologic subtypes predict outcome? Hematol Oncol Clin North Am 11: 893-900, 1997
77. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al: Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: T(14;18) and 3q27 are mutually exclusive. Blood 101:1149-1154, 2003 (Pubitemid 36139390)
78. Hall PA, Richards MA, Gregory WM, et al: The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 154:223-235, 1988 (Pubitemid 18085645)
79. Swerdlow SH, Westermann CD, Pelstring RJ, et al: Growth fraction in centrocytic and follicular center cell lymphomas: Assessment in paraffin sections with a proliferating cell nuclear antigen antibody and morphometric correlates. Hum Pathol 24:540-546, 1993 (Pubitemid 23145807)
80. Logsdon MD, Meyn Jr RE, Besa PC, et al: Apoptosis and the Bcl-2 gene family - patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 44:19-29, 1999 (Pubitemid 29186184)
81. Michels J, Foria V, Mead B, et al: Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 132:743-746, 2006 (Pubitemid 43381636)
82. Zhao WL, Daneshpouy ME, Mounier N, et al: Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 103:695-697, 2004 (Pubitemid 38140106)
83. Farinha P, Masoudi H, Skinnider BF, et al: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169-2174, 2005
84. Zha H, Raffeld M, Charboneau L, et al: Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 84:235-244, 2004 (Pubitemid 41656505)
85. Gulmann C, Espina V, Petricoin III E, et al: Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 11:5847-5855, 2005 (Pubitemid 41170312)
86. Agarwal B, Naresh KN: Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: Study of 116 cases. Am J Hematol 70:278-282, 2002 (Pubitemid 34810504)
87. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681, 2005 (Pubitemid 40825512)
88. Paoluzzi L, Gonen M, Gardner JR, et al: Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111:5350-5358, 2008
89. Dogan A, Bagdi E, Munson P, et al: CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846-852, 2000 (Pubitemid 30366272)
90. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
91. Bilalovic N, Blystad AK, Golouh R, et al: Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol 121:34-42, 2004 (Pubitemid 38090151)
92. Zou GM, Chen JJ, Yoder MC, et al: Knockdown of Pu. 1 by small interfering RNA in CD34+ embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells. Proc Natl Acad Sci U S A 102:13236-13241, 2005
93. Torlakovic EE, Bilalovic N, Golouh R, et al: Prognostic significance of PU. 1 in follicular lymphoma. J Pathol 209:352-359, 2006
94. O'Shea D, O'Riain C, Taylor C, et al: The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112:3126-3129, 2008
95. Sander CA, Yano T, Clark HM, et al: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994-2004, 1993
96. Lo Coco F, Gaidano G, Louie DC, et al: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289-2295, 1993 (Pubitemid 23304250)
97. Davies AJ, Lee AM, Taylor C, et al: A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 19:1459-1465, 2005 (Pubitemid 41136342)
98. Moller MB, Nielsen O, Pedersen NT: Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 41:322-330, 2002 (Pubitemid 35279029)
99. Bjorck E, Ek S, Landgren O, et al: High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105:2908-2915, 2005 (Pubitemid 40446285)
100. Krishnadasan R, Bifulco C, Kim J, et al: Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. Brit J Haematol 135:72-75, 2006 (Pubitemid 44337665)
101. Sakhinia E, Glennie C, Hoyland JA, et al: Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 109:3922-3928, 2007 (Pubitemid 46641745)
102. Kuppers R: Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251-262, 2005
103. Horsman DE, Okamoto I, Ludkovski O, et al: Follicular lymphoma lacking the t(14;18)(q32;q21): Identification of two disease subtypes. Brit J Haematol 120:424-433, 2003 (Pubitemid 36241498)
104. Katzenberger T, Kalla J, Leich E, et al: A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 113:1053-1061, 2009
105. Horsman DE, Connors JM, Pantzar T, et al: Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 30:375-382, 2001 (Pubitemid 32216328)
106. Johansson B, Mertens F, Mitelman F: Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 86:3905-3914, 1995
107. Yunis JJ, Frizzera G, Oken MM, et al: Multiple recurrent genomic defects in follicular lymphoma: A possible model for cancer. N Engl J Med 316:79-84, 1987 (Pubitemid 17052742)
108. Offit K, Jhanwar SC, Ladanyi M, et al: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 3:189-201, 1991
109. Tilly H, Rossi A, Stamatoullas A, et al: Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043-1049, 1994 (Pubitemid 24245867)
110. Hoglund M, Sehn L, Connors JM, et al: Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 39:195-204, 2004 (Pubitemid 38209580)
111. Johnson NA, Al-Tourah A, Brown CJ, et al: Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosomes Cancer 47:1038-1048, 2008
112. Ross CW, Ouillette PD, Saddler CM, et al: Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 13:4777-4785, 2007 (Pubitemid 47294784)
113. Viardot A, Moller P, Hogel J, et al: Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 20:4523-4530, 2002 (Pubitemid 35402955)
114. Cheung KJ, Shah SP, Steidl C, et al: Genomewide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113:137-148, 2009
115. Schwaenen C, Viardot A, Berger H, et al: Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 48:39-54, 2009
116. Fitzgibbon J, Iqbal S, Davies A, et al: Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia 21:1514-1520, 2007 (Pubitemid 46965294)
117. O'Shea D, O'Riain C, Gupta M, et al: Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 113:2298-2301, 2009
118. Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104:2635-2642, 2004 (Pubitemid 39434941)
119. Maloney DG, Smith B, Rose A: Rituximab: Mechanism of action and resistance. Semin Oncol 29:2-9, 2002 (Pubitemid 34171789)
120. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002 (Pubitemid 34525533)
121. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003
122. Ghielmini M, Rufibach K, Salles G, et al: Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Res (SAKK). Ann Oncol 16:1675-1682, 2005 (Pubitemid 41510143)
123. Maloney DG, Pender-Smith B, Unger JM, et al: FcR gamma polymorphisms do not influence progression free survival of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800). Blood 104, 2004 (abstr 589)
124. Boettcher S, Pott C, Ritgen M, et al: Evidence for FcR gamma receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immunochemotherapy. Blood 104, 2004 (abstr 590)
125. Cerhan JR, Wang S, Maurer MJ, et al: Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109: 5439-5446, 2007 (Pubitemid 46890567)
126. Rothman N, Skibola CF, Wang SS, et al: Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 7:27-38, 2006 (Pubitemid 43025390)
127. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004 (Pubitemid 39507628)
128. Glas AM, Kersten MJ, Delahaye LJ, et al: Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105:301-307, 2005 (Pubitemid 40053097)
129. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
130. Koster A, van Krieken JH, Mackenzie MA, et al: Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 11: 154-161, 2005 (Pubitemid 40075790)
131. Streubel B, Chott A, Huber D, et al: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351:250-259, 2004 (Pubitemid 38916042)
132. Shiozawa E, Yamochi-Onizuka T, Yamochi T, et al: Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: Immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract 199:293-302, 2003 (Pubitemid 36939580)
133. Glas AM, Knoops L, Delahaye L, et al: Geneexpression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390-398, 2007 (Pubitemid 350002987)
134. Alvaro T, Lejeune M, Salvado M-T, et al: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24:5350-5357, 2006 (Pubitemid 46623165)
135. Alvaro T, Lejeune M, Camacho FI, et al: The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 91:1605-1612, 2006 (Pubitemid 46032957)
136. Canioni D, Salles G, Mounier N, et al: The poor prognosis value of high intra-tumoral macrophage count in follicular lymphoma patients requires selection of appropriate cut-off and can be circumvented by rituximab therapy. Blood 108, 2006 (abstr 822)
137. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al: A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamidedoxorubicin- vincristine-prednisone. Clin Cancer Res 13:5784-5789, 2007 (Pubitemid 47591642)
138. Mantovani A, Sica A, Sozzani S, et al: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686, 2004 (Pubitemid 39457982)
139. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196:254-265, 2002 (Pubitemid 34189413)
140. Ai WYZ, Czerwinski DK, Horning S, et al: Tumor-infiltrating T cells are not predictive of clinical outcome in follicular lymphoma. Blood 108, 2006 (abstr 824)
141. Carreras J, Lopez-Guillermo A, Fox BC, et al: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957-2964, 2006
142. Farinha P, Han J, Al-Tourah A, et al: The tumor microenvironment measured by flow cytometry predicts overall survival and transformation risk in follicular lymphoma. Blood 108, 2006 (abstr 2406)
143. Lee AM, Clear AJ, Calaminici M, et al: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24:5052-5059, 2006 (Pubitemid 46631409)
144. Strickler JG, Copenhaver CM, Rojas VA, et al: Comparison of "host cell infiltrates" in patients with follicular lymphoma with and without spontaneous regression. Am J Clin Pathol 90:257-261, 1988
145. de Jong D, Koster A, Hagenbeek A, et al: Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94:70-77, 2009
146. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nature reviews 6:295-307, 2006
147. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004 (Pubitemid 39273735)
148. Farinha P, Campo E, Banham A, et al: The architectural pattern of FOXP3+ T cells is an independent predictor of survival in patients with follicular lymphoma (FL). Mod Pathol 19:1043a, 2006
149. Carreras J, Lopez-Guillermo A, Roncador G, et al: High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27:1470-1476, 2009
150. Acker B, Hoppe RT, Colby TV, et al: Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1:11-16, 1983 (Pubitemid 13066136)
151. Cullen MH, Lister TA, Brearley RI, et al: Histological transformation of non-Hodgkin's lymphoma: A prospective study. Cancer 44:645-651, 1979 (Pubitemid 10220149)
152. Ersboll J, Schultz HB, Pedersen-Bjergaard J, et al: Follicular low-grade non-Hodgkin's lymphoma: Long-term outcome with or without tumor progression. Eur J Haematol 42:155-163, 1989 (Pubitemid 19064945)
153. Garvin AJ, Simon RM, Osborne CK, et al: An autopsy study of histologic progression in non-Hodgkin's lymphomas: 192 cases from the National Cancer Institute. Cancer 52:393-398, 1983 (Pubitemid 13073462)
154. Hubbard SM, Chabner BA, DeVita Jr VT, et al: Histologic progression in non-Hodgkin's lymphoma. Blood 59:258-264, 1982 (Pubitemid 12172012)
155. Oviatt DL, Cousar JB, Collins RD, et al: Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer 53:1109-1114, 1984
156. Qazi R, Aisenberg AC, Long JC: The natural history of nodular lymphoma. Cancer 37:1923-1927, 1976
157. Muller-Hermelink HK, Zettl A, Pfeifer W, et al: Pathology of lymphoma progression. Histopathology 38:285-306, 2001 (Pubitemid 34225023)
158. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al: Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677-4685, 1998 (Pubitemid 28270317)
159. Lossos IS: Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23:6351-6357, 2005
160. Lossos IS, Alizadeh AA, Diehn M, et al: Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 99:8886-8891, 2002 (Pubitemid 34693653)
161. Lossos IS, Levy R: Higher grade transformation of follicular lymphoma: Phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 13:191-202, 2003 (Pubitemid 36577691)
162. Macpherson N, Lesack D, Klasa R, et al: Small noncleaved, non-Burkitt's (Burkitt-Like) lymphoma: Cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17:1558-1567, 1999
163. Yano T, Jaffe ES, Longo DL, et al: MYC rearrangements in histologically progressed follicular lymphomas. Blood 80:758-767, 1992
164. Akasaka T, Lossos IS, Levy R: BCL6 gene translocation in follicular lymphoma: A harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102:1443-1448, 2003 (Pubitemid 36988055)
165. Matolcsy A, Warnke RA, Knowles DM: Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma. Ann Oncol 8:119-122, 1997
166. Berglund M, Enblad G, Thunberg U, et al: Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma. Mod Pathol 20:63-75, 2007 (Pubitemid 44967951)
167. Bernell P, Jacobsson B, Liliemark J, et al: Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B-cell lymphoma: A study by FISH. Br J Haematol 101:487-491, 1998 (Pubitemid 28266943)
168. Boonstra R, Bosga-Bouwer A, Mastik M, et al: Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma. Hum Pathol 34:915-923, 2003 (Pubitemid 37169622)
169. Hough RE, Goepel JR, Alcock HE, et al: Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br J Cancer 84:499-503, 2001 (Pubitemid 32215877)
170. Martinez-Climent JA, Alizadeh AA, Segraves R, et al: Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101:3109-3117, 2003 (Pubitemid 36858004)
171. de Vos S, Hofmann WK, Grogan TM, et al: Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 83:271-285, 2003 (Pubitemid 36255371)
172. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al: Involvement of multiple signaling pathways in follicular lymphoma transformation: P38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A 100:7259-7264, 2003 (Pubitemid 36706426)
173. Davies AJ, Rosenwald A, Wright G, et al: Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 136:286-293, 2007 (Pubitemid 46020756)
174. Koster A, Tromp HA, Raemaekers JM, et al: The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 92:184-190, 2007
175. Wang SA, Wang L, Hochberg EP, et al: Low histologic grade follicular lymphoma with high proliferation index: Morphologic and clinical features. Am J Surg Pathol 29:1490-1496, 2005 (Pubitemid 41513299)
176. Chang KC, Huang X, Medeiros LJ, et al: Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol 201:404-412, 2003 (Pubitemid 37408261)
177. Hilchey SP, De A, Rimsza LM, et al: Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory t cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+ CD25- T Cells. J Immunol 178:4051-4061, 2007 (Pubitemid 46492353)
178. Porter DL, Levine BL, Bunin N, et al: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107:1325-1331, 2006 (Pubitemid 43242365)
179. Wahlin BE, Sander B, Christensson B, et al: CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 13:388-397, 2007 (Pubitemid 46225341)
180. Karube K, Guo Y, Suzumiya J, et al: CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109:3076-3079, 2007 (Pubitemid 46482109)
181. Naresh KN: MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 92:267-268, 2007
182. Horsman DE, Okamoto I, Ludkovski O, et al: Follicular lymphoma lacking the t(14;18)(q32;q21): Identification of two disease subtypes. Br J Haematol 120:424-433, 2003 (Pubitemid 36241498)
183. Iqbal S, Jenner MJ, Summers KE, et al: Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: Methodology and clinical significance. Br J Haematol 124:325-328, 2004 (Pubitemid 38167982)
184. Johnson NA, Al-Tourah A, Horsman DE, et al: Insights into disease evolution of transformed follicular lymphoma derived from cytogenetics. Blood 106, 2005 (abstr 180)
185. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al: Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93:3081-3087, 1999 (Pubitemid 29200801)
186. Martinka M, Comeau T, Foyle A, et al: Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma. Clin Invest Med 20: 364-370, 1997 (Pubitemid 28052324)
187. Pinyol M, Cobo F, Bea S, et al: P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984, 1998 (Pubitemid 28227549)
188. Bastard C, Deweindt C, Kerckaert JP, et al: LAZ3 rearrangements in non-Hodgkin's lymphoma: Correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 83:2423-2427, 1994 (Pubitemid 24135832)